Condition 1: Heart failure. Condition 2: Hypertension. Condition 3: Diabetes Mellitus. Condition 4: Dyslipidemia. Condition 5: Kidney Function. Condition 6: Individualized rehabilitation nursing care with follow-ups for elderly patients with Heart Failure. Condition 7: Care involving the use of rehabilitation procedures for cardiac patients. Heart failure Essential (primary) hypertension Type 2 diabetes mellitus Disorders of lipoprotein metabolism and other lipidemias Chronic kidney disease
Conditions
Interventions
Intervention 1: Intervention group: The intervention consists of 5 stages, which are provided by the researcher to elderly people with heart failure. Objective: To investigate the effect of providing
Sponsors
Yazd University of Medical Sciences
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: Willingness to participate in the study Patients over 60 years of age Patients able to walk 4 meters or more with or without the use of assistive devices. Patients living in their own home or with their children Diagnosis of heart failure with an ejection fraction of 20-45% and dyspnea grades I, II, and III The patient or active companion has a smart phone The patient or their companion is able to read and write Access to standard home measurement devices or the ability to visit a health center
Exclusion criteria
Exclusion criteria: Non-Yazdi patient or inability to attend in the first 2 weeks End-stage heart failure or kidney disease Having respiratory illnesses that prevent activity Patients with cognitive disorders and dementia The patient's candidacy for surgery as heart failure treatment Having ventricular assist devices Inability to measure and report physiological parameters having severe heart failure symptoms
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Health-Related Quality of Life. Timepoint: The measurement time points include baseline at the start of the study, the end of week 12 after study initiation (end of intervention phase), and the end of week 16 after study initiation (end of follow-up phase). Method of measurement: Measurement tool: The Minnesota Living with Heart Failure Questionnaire.;Self-Care Behavior. Timepoint: The measurement time points include baseline at the start of the study, the end of week 12 after study initiation (end of intervention phase), and the end of week 16 after study initiation (end of follow-up phase). Method of measurement: Measurement tool: European heart failure self-care behavior questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hospital Readmission. Timepoint: The measurement time points include the end of week 12 after study initiation (end of the intervention phase) and the end of week 16 after study initiation (end of the follow-up phase). Method of measurement: Measurement tool: Recorded in the follow-up form (based on patient self-report, review of case documentation, and follow-up calls).;Average blood pressure. Timepoint: The measurement time points include baseline at the start of the study, the end of week 12 after study initiation (end of intervention phase), and the end of week 16 after study initiation (end of follow-up phase). Method of measurement: Measuring blood pressure with a validated digital blood pressure monitor by the patient at home or in healthcare centers.;Weight. Timepoint: The measurement time points include baseline at the start of the study, the end of week 12 after study initiation (end of intervention phase), and the end of week 16 after study initiation (end of follow-up phase). Method of measurement: Measuring weight with a reliable home scale at home or in health centers.;Edema. Timepoint: The measurement time points include baseline at the start of the study, the end of week 12 after study initiation (end of intervention phase), and the end of week 16 after study initiation (end of follow-up phase). Method of measurement: Measuring ankle circumference at home with a tape measure and performing the pitting test.;Fast blood sugar. Timepoint: The measurement time points include baseline at the start of the study, the end of week 12 after study initiation (end of intervention phase), and the end of week 16 after study initiation (end of follow-up phase). Method of measurement: Measured in the laboratory using an automatic biochemistry device.;HbA1c level. Timepoint: The measurement time points include baseline at the start of the study, the end of week 12 after study initiation (end of intervention phase), and the end of week 16 after study initiation (end o | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFatemeh Bakhshi
Yazd University of Medical Sciences
Outcome results
None listed